• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

United States Market for In Vitro Diagnostic (IVD) Tests

$4,000.00 – $8,000.00

Clear
SKU: 21-026 Category: Diagnostics Market Research Tags: Cancer, Clinical Chemistry, clinical labs, COVID-19, diabetes, healthcare, Hematology, histology, Immunoassay, in vitro diagnostics, Infectious Disease, ivd, molecular diagnostics, molecular test kits, point of care, reagents, urinalysis Pages: 180
  • Description
  • Table of Contents
  • Latest reports

Description

The U.S. market dominates the IVD industry AND remains the core geographical IVD market in the world. Yet this major multi-billion-dollar IVD market is in a state of flux, trying to manage a myriad of issues, all of which collide with a huge system that costs more than any other in the world.

COVID-19 had a profound effect on the IVD diagnostic industry – some segments exploded and others languished. At this point in time, it is hard to predict how the coronavirus will impact the forecast years to 2025, but Kalorama has attempted to provide insight into the industry by conversing with market participants and government entities. It is realistic to assume the market for COVID-19 will remain a component of the IVD market as the continued prevalence of the virus and the evolving variants are expected to remain. It should be noted that the market can be uncertain and ongoing research will help determine the long-term path of the segment in the coming months to years.

Demographic aging is also one of the primary market influencing trends for IVD in the United States. Aging is associated with rising incidences and rates of prevalence for several non-infectious diseases including diabetes and cancer. Individuals over the age of 60 are estimated to average at least four times the number of clinical tests of younger individuals.

This latest report from Kalorama Information, United States Market for In Vitro Diagnostic Tests, discusses these and other trends shaping the present and future of the IVD market in America. The report discusses the following IVD market segments in the United States:

  • Clinical Chemistry
  • Microbiology (Traditional) – Identification and Antibiotic Susceptibility Testing (ID/AST)
  • Microbiology – Molecular- Infectious Disease
  • Point-of-Care (POC) Tests – Diabetes
  • Point-of-Care (POC) Tests – All Other
  • Immunoassays – Infectious Disease (non-POC)
  • Immunoassays – Other
  • Molecular – Non-infectious Disease
  • Hematology
  • Coagulation (non-POC)
  • Histology
  • Blood Testing and Typing
  • Others

In addition, the report profiles the top players in the U.S. IVD market. The profiles cover notable corporate events and developments from 2018, 2019 and 2020. Featured companies include:

  • ABBOTT DIAGNOSTICS
  • BECKMAN COULTER, INC. / DANAHER
  • BECTON, DICKINSON AND COMPANY (BD)
  • BIOMÉRIEUX
  • BIO-RAD LABORATORIES, INC.
  • CEPHEID / DANAHER
  • DANAHER CORPORATION
  • HOLOGIC, INC.
  • ORTHO CLINICAL DIAGNOSTICS (ORTHO)
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS
  • SIEMENS HEALTHINEERS (SIEMENS)
  • SYSMEX CORPORATION
  • THERMO FISHER SCIENTIFIC INC.

Table of Contents

CHAPTER 1: EXECUTIVE SUMMARY
U.S. IVD MARKET

      • Table 1-1: U.S. IVD Market by Segment 2020-2025 (in millions $)
      • Figure 1-1: U.S. IVD Market Segments by % of the total U.S. IVD Market 2020

TOP TIER U.S. IVD MARKET PARTICIPANTS AND RANKINGS

      • Table 1-2: U.S. IVD Market Rankings by Estimated 2020 Revenue – Top 12 Companies

CONCLUSIONS

CHAPTER 2: INTRODUCTION TO U.S. HEALTH CARE
THE UNITED STATES AND IN VITRO DIAGNOSTICS
U.S. PATIENT POPULATION

  • Healthcare System Utilization
  • Aging
      • Table 2-1: Historical and Projected U.S. Aged Populations (60+) (% Share of Total Population, Population in Millions) (1950-2050)
  • Disease Prevalence and Incidence
      • Figure 2-2 : Rate of New Cancers by Age Group , All Types US 2013-2017
      • Table 2-3 U.S. Cancer Deaths 2013-2017 per 100,000 by Type
      • Table 2-4: Reported Cases of Selected Notifiable Diseases , U.S. 2016-2018 by Case Count
  • U.S. Clinical Lab Expenditure
      • Table 2-5: U.S. Clinical Lab Market by Channel 2020-2025 by % of Market
    • Hospital-Acquired Infections (HAIs)
    • Preventive Health Care
    • Product Innovation from Value-Based Pricing

CLINICAL TESTING UNDER MEDICARE – REIMBURSEMENT CUTS AND MARKET-BASED PRICING

  • Protecting Access to Medicare Act of 2014 (PAMA)
      • Table 2-6: Proposed Clinical Diagnostic Laboratory Test Rates, 2020-2023
    • Impact of CARES Act on PAMA

PERSONALIZED MEDICINE AND NGS
LABORATORY-DEVELOPED TESTS (LDTS)

  • Changes Resulting from COVID-19 Pandemic

U.S. HEALTHCARE INFRASTRUCTURE AND TESTING CHANNELS

  • Hospitals
  • Independent Labs
  • Physician Office Laboratories
  • Self-Testing
  • Retail Clinics

CONCLUSIONS

CHAPTER 3: U.S. IVD MARKET ANALYSIS
CLINICAL CHEMISTRY

      • Table 3-1: U.S. Clinical Chemistry Market (General Chemistry, Blood Gases, Urinalysis) 2020-2025 (in millions $)
      • Figure 3-1: U.S. Clinical Chemistry Market (2020-2025) ($ millions)

MICROBIOLOGY AND VIROLOGY – ID/AST AND MOLECULAR

      • Table 3-2: US ID/AST Microbiology ID/AST Market (ID/AST Auto, ID/AST Panels, Blood Culture, Chromogenic Media, Rapid Micro 2020-2025 In millions $
      • Figure 3-2: U.S. ID/AST Microbiology Market (Auto ID/AST, Manual ID/AST, Blood Culture, Chromogenic Media, Rapid, Micro, COVID-19(2020-2025) ($ millions)
  • Molecular Infectious Disease
      • Table 3-3: U.S. Molecular Infectious Disease by Segment ( HAI/Sepsis, HIV, Hepatitis, GC/Chlamydia, Respiratory, Mycobacteria/TB, COVID-19, Other Molecular including Parasitology, Mycology, Malaria, Chagas, Dengue etc.) 2020-2025 in Millions of $
      • Figure 3-3: U.S. Molecular Microbiology / Virology Market (2020-2025) ($ millions)

POINT-OF-CARE TESTING

      • Table 3-4: U.S. Point-of-Care (POC) Diagnostics Markets – Glucose, Blood & Electrolytes, Coagulation, Cardiac Markers, Drugs of Abuse, Pregnancy & Fertility, Fecal Occult Blood, Infectious Disease, Lipid, Cancer Tumor Markers, Urine, Miscellaneous ($ millions)
      • Figure 3-4: U.S. POC Diabetes Market 2020-2025 (in millions $)
      • Figure 3-5: U.S. POC Market without Diabetes 2020-2025 (in millions $)

IMMUNOASSAYS

  • Non-Infectious Disease Immunoassay
      • Table 3-5: U.S. Immunoassays Market – Non Infectious (Cardiac Markers, Tumor Markers, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs, Vitamin D) and Others including HbA1c Lab, Drugs of Abuse (2020-2025) ($ millions)
      • Figure 3-6: U.S. Immunoassay-Non-infectious including Cardiac Markers, Tumor Markers, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs, Vitamin D and others (inc. HbA1c lab and Drugs of Abuse) in millions $
  • Infectious Disease Immunoassay
      • Table 3-6: U.S. Immunoassays Market – Infectious (Hepatitis, HIV, STDs, ToRCH, Respiratory, HAIs/Sepsis, Others including Parasitology, Mycology, Others) 2020-2025 (in millions $)
      • Figure 3-8: U.S. Immunoassay Infectious Disease (Hepatitis, HIV, STDs, ToRCH, Respiratory, HAI/Sepsis, COVID-19, Others) 2020-2025 in millions $

MOLECULAR NON-INFECTIOUS DISEASE DIAGNOSTICS

      • Figure 3-9: U.S. Molecular Non-Infectious Disease Diagnostics Market (2020-2025) ($ millions)

COAGULATION

      • Table 3-7: U.S. Coagulation Diagnostics Market by Segment , PT/INR, Molecular-lab Thrombophilia SNPs, D-Dimer, 2020-2025 (in millions $)
      • Figure 3-10: U.S. Coagulation Diagnostics Market (2020-2025) ($ millions)

HISTOLOGY

      • Table 3-8: U.S. Histology/Cytology IVD Market by Segment including Pap Tests, in situ Hybridization, Immunohistochemistry, Traditional non-Pap Stains, HPV Molecular) 2020-2025 in millions $
      • Figure 3-11: U.S. Histology and Cytology Diagnostics Market (2020-2025) ($ millions)

HEMATOLOGY

      • Table 3-9: U.S. Lab-based Hematology Market by Analyte 2020-2025 (in millions $)
      • Figure 3-12: U.S. Hematology Diagnostics Market (2020-2025) ($ millions)

BLOOD TESTING AND TYPING

      • Table 3-10: U.S. Blood Testing and Typing by Segment 2020-2025 ( in millions $)
      • Figure 3-13: U.S. Blood Testing and Typing Diagnostics Market (2020-2025) ($ millions)

TOTAL U.S. IVD MARKET

      • Table 3-11: U.S. IVD Market including COVID-19 by Segment 2020-2025 (in millions $)
      • Figure 3-14: U.S. IVD Market Segments by % 2020

CHAPTER 4: TOP TIER U.S. IVD MARKET PLAYERS
ABBOTT DIAGNOSTICS

  • Recent Revenue History
      • Table 4-1: Abbott Diagnostic Revenues 2016-2020 (millions $)
      • Figure 4-1: 2020 IVD U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-2: Global Abbott Diagnostic Revenues 2016-2020 (millions $)
  • Alere Acquisition Update and Point of Care
  • Core Lab
  • Hematology
  • Blood Banking
  • Infectious Diseases – Molecular
  • Diabetes
  • HIV Point of Care
  • i-STAT Business
  • COVID-19

BECKMAN COULTER, INC. / DANAHER

  • Recent Revenue History
      • Table 4-3: Beckman Coulter Diagnostic Revenues 2016-2020 (millions $)
      • Figure 4-2: 2020 IVD U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-4: Global Beckman Coulter Revenues in Selected Test Segments 2017-2020 (millions $) estimated
  • Hematology
  • Hematology IT
  • Clinical Chemistry
  • Immunoassays
  • Coagulation
  • Microbiology
  • Urinalysis
  • Clinical Information Technology
  • Molecular Tissue Analysis
  • Flow Cytometry
  • A Fight for Brain Natriuretic Peptide (BNP) Assay Rights
  • Beckman Coulter Life Sciences
  • Collaborations
  • COVID-19

BECTON, DICKINSON AND COMPANY (BD)

  • Recent Revenue History
      • Table 4-5: BD Diagnostic Revenues 2016-2020 (millions $)
      • Figure 4-3: 2020 IVD U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-6: Global BD Revenues in Selected Test Segments 2019, 2020 (millions $) estimated
      • Table 4-7: Global BD Revenues in Flow Cytometry 2016- 2020 (millions $)
  • Cytology
  • Molecular Microbiology
  • Traditional Microbiology – ID/AST
  • Blood Culture
  • Blood culture collection products for the preanalytical phase
  • Hospital Acquired Infections
  • Blood Collection
  • Mass Spectrometry
  • Flow Cytometry
  • COVID-19

BIOMÉRIEUX

  • Recent Revenue History
      • Table 4-8: bioMerieux IVD Revenues 2016-2020 (millions $)
      • Figure 4-4: 2020 IVD U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-9: bioMerieux Revenues in Selected Test Segments 2016-2020 (millions $)
  • Traditional Microbiology
  • Blood Culture
  • Immunoassays
  • BIOFIRE Diagnostics Business
  • COVID-19

BIO-RAD LABORATORIES, INC.

  • Recent Revenue History
      • Table 4-10: Bio-Rad Diagnostics Revenues 2016-2020 (millions $)
      • Figure 4-5: 2020 IVD U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-11 Global Bio-Rad Revenues in Selected Test Segments 2016-2020 (millions $)
  • Blood Bank
  • Diabetes
  • Immunoassays
  • COVID-19

CEPHEID / DANAHER

  • Recent Revenue History
      • Table 4-12: Cepheid Revenues 2016-2020 (millions $)
  • GeneXpert Xpress Line
  • High Burden Expansion
  • India
  • Tuberculosis
  • Microbiology
  • POC Testing
  • Cancer
  • COVID-19

DANAHER CORPORATION

    • Recent Revenue History
      • Table 4-13: Danaher Diagnostics Revenues 2015-2019 (millions $)
      • Figure 4-6: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-14: Global Danaher Revenues in Business Segments 2016-2020 (millions $)

HOLOGIC, INC.

  • Recent Revenue History
      • Table 4-15: Hologic Revenues 2016-2020 (millions $)
      • Figure 4-7: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-16: Global Hologic Revenues in Selected Test Segments 2016-2020 (millions $)
  • PANTHER Molecular System
  • HIV Testing
  • Sexually Transmitted Infections
  • Cytology
  • COVID-19

ORTHO CLINICAL DIAGNOSTICS (ORTHO)

  • Recent Revenue History
      • Table 4-17: Ortho Clinical Diagnostics Revenues 2016-2020 (millions $)
      • Figure 4-8: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-18: Global Ortho Clinical Diagnostics Revenues in Selected Test Segments 2019-2020 (millions $)
  • Blood Bank
  • Core Lab / Immunoassays
  • COVID-19

QIAGEN N.V.

  • Recent Revenue History
      • Table 4-19: QIAGEN N.V. IVD Revenues 2016-2020 (millions $)
      • Figure 4-9: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-20: Global QIAGEN IVD Revenues by Type, 2016-2020 (million)
  • Tuberculosis
  • Lyme Disease
  • Molecular Expansion
  • Precision Medicine / Companion Diagnostics
  • Molecular Microbiology
  • Prenatal Testing
  • Next Generation Sequencing
  • Digital PCR
  • Liquid Biopsy
  • COVID-19

ROCHE DIAGNOSTICS

  • Recent Revenue History
      • Table 4-21: Roche IVD Diagnostics Revenues 2016-2020 (millions $)
      • Figure 4-10: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-22: Global Roche IVD Diagnostics Revenues by Type, 2016-2020 (million)
  • Hematology
  • Core Lab
  • Immunoassays
  • Core Molecular
  • Digital PCR
  • Diabetes Care
  • Coagulation
  • cobas Liat System – POC
  • HPV
  • Blood Bank
  • Cancer Companion Testing
  • COVID-19

SIEMENS HEALTHINEERS (SIEMENS)

  • Recent Revenue History
      • Table 4-23: Siemens Healthineers IVD Revenues 2016-2020 (millions $)
      • Figure 4-11: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-24: Global Siemens Healthineers IVD Revenues by Type, 2020 (million)
  • Core Lab
  • Immunoassays
  • Hematology
  • Molecular
  • Coagulation
  • Acute Care – POC
  • COVID-19

SYSMEX CORPORATION

  • Recent Revenue History
      • Table 4-25: Sysmex IVD Revenues 2016-2020 (millions $)
      • Figure 4-12: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-26: Global Sysmex IVD Revenues by Type, 2016-2020 (million)
  • Hematology
  • Coagulation
  • Urinalysis
  • Immunoassays
  • Flow Cytometry
  • Precision Medicine / Companion Test Diagnostics
  • Oncology
  • COVID-19

THERMO FISHER SCIENTIFIC INC.

  • Recent Revenue History
      • Table 4-27: Thermo Fischer IVD Revenues 2016-2020 (millions $)
      • Figure 4-13: 2020 IVD Diagnostic U.S. Revenues vs Non U.S. IVD Revenues ($in millions) estimated
      • Table 4-28: Global Thermo Fisher IVD Revenues by Type, 2016-2020 (million)
  • Immunoassays
  • Microbiology
  • Next Generation Sequencing
  • qPCR
  • Mass Spectrometry
  • COVID-19
    Clinical Laboratory Services Market, 8th Edition
    May 16, 2023
    COVID-19 Testing Markets, 2023
    April 24, 2023
    The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 10th Edition
    April 13, 2023
    Hematology and Coagulation Markets, 2023
    April 6, 2023

Related products

  • Placeholder image

    Molecular Imaging Agents and Systems – A Market Briefing

    $995.00 – $1,990.00
  • Placeholder image

    Nucleic Acid-Based Therapeutics: World Markets, Developments, and Applications

    $3,500.00 – $7,000.00
  • Placeholder image

    Diagnostics for Emerging Infectious Disease Threats, Volumes I – III

    $3,995.00 – $7,990.00
  • Placeholder image

    The Worldwide Market for In Vitro Diagnostic Tests, 5th Edition

    $3,900.00 – $7,800.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • New Kalorama Report Pegs Clinical Lab Services Market at 168BN May 18, 2023
  • WHO Reports Lowered Threat Level of COVID-19; What Does it Mean for Testing? May 9, 2023
  • SDi Releases Flagship Market Research Report on Analytical and Life Science Instruments: The Global Assessment Report May 3, 2023
  • Despite Declines, COVID-19 Still a Large IVD Market May 1, 2023
  • Single Cell Genomics Market Reaches $1 Billion April 27, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Remote Patient Monitoring and Telehealth Markets, 12th EditionClinical Laboratory Services Market, 6th Edition
Scroll to top